Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic castration resistant prostate cancer were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results indicate that metastatic castration resistant prostate cancer is not a single disease and that biomarkers may play an essential role in deciding on best therapy for your patients. In this activity, you will listen to two leading experts in metastatic castration resistant prostate cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with metastatic castration resistant prostate cancer.
Upon completion of this activity, participants will be able to:
- Explain the molecular targets of metastatic castration resistant prostate cancer
- Analyze the clinical trial data of therapies used to treat metastatic castration resistant prostate cancer that were presented at ESMO 2016
- Develop data-driven, individualized treatment plans to improve treatment selection and outcomes for patients with metastatic castration resistant prostate cancer
Joaquim Bellmunt, MD PhD
Dana-Farber Cancer Institute, Boston, USA
Karen E. Knudsen, PhD
Sidney Kimmel Cancer Center, Philadelphia, USA
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Joaquim Bellmunt, MD PhD
Consultant/Advisor: Astellas Pharma US, Inc.; Genentech, Inc.; Merck & Co., Inc.; Sanofi; Pierre Fabre Laboratories
Grant/Research Support: Sanofi; Novartis AG
Speaker's Bureau: None
Karen E. Knudsen, PhD
Grant/Research Support: Celgene Corporation
Speaker's Bureau: Sanofi
Stock/Ownership: Pfizer inc.
Non-faculty: Marcel Meijer; Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi Genzyme.
Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.